IQVIA Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 results exceeded expectations with strong growth in both commercial and RDS segments, supported by robust demand and AI-driven productivity. AI adoption is accelerating across top pharma clients, driving new offerings and operational efficiencies. Capital deployment favors buybacks, with ongoing M&A activity and increased investment in AI initiatives.
-
Record Q1 revenue and EPS exceeded guidance, driven by strong organic growth in both Commercial and R&D Solutions, robust AI adoption, and a record backlog. Full-year guidance was reaffirmed and EPS outlook raised, with continued strong demand and constructive market conditions.
-
AI is driving revenue and margin growth, with over 150 agents deployed and plans for 500+ by 2027. Demand is strong, especially in biotech, which is expanding into clinical and commercial stages. Recent acquisitions enhance drug discovery capabilities, while productivity programs and automation support margin expansion.
-
AI is driving efficiency and new revenue streams, supported by proprietary data and advanced agent deployment. Market stability has returned post-COVID, with biotech and large pharma fueling growth. The Cedar Gate acquisition enhances US patient analytics and real-world evidence capabilities.
-
Strong Q4 growth and stable margins were reported, with Commercial Solutions and R&DS segments showing momentum. AI is seen as a major opportunity, leveraging proprietary data and new agentic solutions, while only minor consulting areas face risk. Leadership transition emphasizes continuity and optimism for future growth.
Fiscal Year 2025
-
Delivered strong Q4 and full-year 2025 results with 6% revenue growth and robust free cash flow. 2026 guidance projects continued growth, supported by AI-driven solutions, strategic acquisitions, and strong demand across segments.
-
Q3 results were strong, with bookings and RFPs signaling improving demand as industry uncertainty recedes. Pricing and margins have stabilized, and long-term growth targets remain intact, supported by operational efficiencies and AI initiatives.
-
Q3 saw strong revenue and record free cash flow, with robust bookings and backlog growth. Guidance for 2025 was reaffirmed, with all segments performing well and AI initiatives expanding to drive future efficiency and margin improvement.
-
Record Q2 revenue exceeded $4 billion, with strong TAS and R&DS performance and robust AI-driven innovation. Guidance for FY25 was raised, though margin pressure persists due to mix and pricing. Backlog and bookings hit new highs, supporting a positive outlook.
-
Revenue and cash flow exceeded guidance, with TAS and RWE segments showing strong growth. Policy uncertainty and funding cycles slowed bookings, but demand indicators and backlog remain positive. Capital deployment favors M&A and buybacks, with a focus on growth areas in TAS and R&DS.
-
Q1 revenue and profit exceeded expectations, led by strong TAS growth and record backlog, despite sector uncertainty delaying R&D Solutions bookings. Full-year revenue guidance was raised, with profit guidance reaffirmed, and significant AI-driven productivity gains are underway.
-
Revenue is split between CRO and TAS/CSMS, with long-term industry stability and a shift away from short-term metrics. Elevated cancellations are expected to ease by mid-year, and growth is driven by diversified customer mix, hybrid models, and ongoing M&A focus.
Fiscal Year 2024
-
Delivered strong 2024 results with 5.5% revenue growth (ex-COVID), adjusted EPS up 9%, and record free cash flow, despite industry headwinds. Renewed all major pharma partnerships, expanded AI innovation, and reaffirmed 2025 guidance for continued growth.
-
IQVIA projects 6%-9% mid-term annual growth, driven by integrated data, AI, and global capabilities, with 2025 guidance of 4%-7% revenue growth and 5%-9% EPS growth. Despite headwinds, margin expansion and strong client partnerships underpin a positive long-term outlook.
-
Q3 results exceeded expectations, led by strong TAS growth and margin expansion, while R&DS faced headwinds from cancellations and trial delays. Despite near-term volatility, backlog and pipeline remain healthy, and 2025 is expected to see solid growth with incremental margin pressure.
-
Revenue and adjusted EPS exceeded guidance, driven by strong TAS growth and disciplined cost management, while R&DS faced cancellations and trial delays. Backlog hit a record $31.1B, and 2024 guidance was updated to reflect short-term headwinds, with mid-single-digit growth expected into 2025.
-
Recovery in TAS and continued R&DS strength support confidence in year-end guidance. Margins remain robust despite pricing pressures, aided by cost controls and strong data-driven AI initiatives. U.S. leads in growth, while China and Europe present long-term opportunities.
-
Q2 saw 5% revenue growth (ex-FX/COVID) and 8.6% adjusted EPS growth, with a record $30.6B backlog and strong R&DS bookings. Full-year guidance was reaffirmed, with TAS and R&DS expected to grow 5% and 7%, respectively, amid ongoing pricing pressure and robust AI-driven wins.